Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasisâ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). Source
No articles found.
Achieve is a specialty pharmaceutical company committed to advancing cytisinicline...
Achieve is a specialty pharmaceutical company c...
Inogenâs mission to improve the quality of life of supplemental oxygen users beg...
Inogenâs mission to improve the quality of li...
BelleIQ operates ALLIES, an online marketplace selling health & wellness products ...
BelleIQ operates ALLIES, an online marketplace ...
PTC is a science-led, global biopharmaceutical company focused on the discovery, d...
PTC is a science-led, global biopharmaceutical ...
Agile Therapeutics is a forward-thinking women's healthcare company dedicated to f...
Agile Therapeutics is a forward-thinking women'...
Lexicon Pharmaceuticals is a fully integrated biopharmaceutical company that is ap...
Lexicon Pharmaceuticals is a fully integrated b...
ContraFect is a clinical-stage biotechnology company focused on discovering and de...
ContraFect is a clinical-stage biotechnology co...
Join the National Investor Network and get the latest information with your interests in mind.